eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
he said the case could have been more complicated. “everyone’s pain threshold is a little different. an embolization is pretty painful regardless.
.
.
.
friday, 18 may, 2018
.
.
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid.